claseprubart — Regulatory decision
YE'26
Claseprubart 2026 milestones: Ph. 3 gMG trial initiation (mid'26), Ph. 2 MMN top-line data (Q4'26) and Ph. 3 CIDP Part B top-line guidance by YE'26Source filing
DNTH biotech catalysts & pipeline
DIANTHUS THERAPEUTICS INC · Data as of 2026-09-08
Upcoming catalysts
DNTH212 — Initial data
Late 2026
A two-part Phase 1 study in China in healthy volunteers (Part A) and patients with Systemic Lupus Erythematosus (Part B) was initiated in December 2025, with Phase 1 healthy volunteer data anticipated by year-end 2026.Source filing
claseprubart — Topline data
December '26
Phase 2 MoMeNtum trial of claseprubart in MMN exceeded its original enrollment target of 36 patients; top-line results with 46 patients on track for December '26Source filing
claseprubart — Topline data
2H'28
Phase 3 EMERGE registrational trial of claseprubart in gMG evaluating 300mg/2mL Q2W and 300mg/2mL Q4W initiated in June ‘26, with top-line results anticipated in 2H'28Source filing